Novo Nordisk's stock has experienced fluctuations, with some reports indicating it has slid or declined while others suggest it has increased, though not always keeping pace with the broader market. The company's outlook, particularly regarding its obesity drugs, may be impacted by pricing pressure. The stock's performance has been the subject of various analyses, with some noting unusual put option volume and questioning whether it may be overvalued.